PTPN11 and lung adenocarcinoma: By comprehensive phosphoproteomics characterization of 110 tumors and 101 matched NATs, three candidate drug targets were identified for lung adenocarcinoma (LUAD), including SOS1 inhibition in KRAS mutant, PTPN11/Shp2 inhibition in both ALK fusion and EGFR mutant tumors, and STK11 mutation in neutrophil degranulation.62